Trials / Completed
CompletedNCT00597896
Cognitive Enhancement in Bipolar Disorder
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Northwell Health · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine whether the medication pramipexole (Mirapex) may be able to improve cognitive problems (i.e. difficulties with thinking, memory, and concentration) that may be associated with bipolar disorder.
Detailed description
To address the primary aim, the study is an eight-week, randomized, double-blind, placebo-controlled treatment trial of pramipexole in 50 euthymic bipolar I and II disorder (BPD) patients, who demonstrate cognitive impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pramipexole | po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2011-04-01
- Completion
- 2011-04-01
- First posted
- 2008-01-18
- Last updated
- 2015-06-12
- Results posted
- 2015-06-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00597896. Inclusion in this directory is not an endorsement.